Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its first quarter ended March 31, 2023, and updated financial expectations for the full year…
Extend Biosciences (“ExtendBio”), a clinical stage biopharmaceutical company utilizing a proprietary platform technology to develop advanced therapeutic peptides, today announced positive results from its first-in-human trial of EXT608. An interim data analysis shows that EXT608 was safe and well tolerated,…
A leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the first quarter ended March 31, 2023, and provided a business update. “Validation of a GMP stem cell gene…
Bicycle Therapeutics plc (NASDAQ: BCYC) and Orano Med, two biotechnology companies respectively, announce pre-clinical results. Bicycle is pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology and Orano Med is developing innovative radioligand…
National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today reported its financial results for the first quarter ended April 1, 2023. Reade Fahs, chief executive officer, stated, “Amidst an uncertain macro environment, we delivered positive comparable sales…
Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2022 (period ended March 31, 2023), delivering or exceeding management guidance, driven by the performance of its Growth & Launch Products. Takeda president and chief executive officer, Christophe Weber, commented:“FY2022…
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform to help physicians detect heart attacks anytime, anywhere as well as diagnose other common heart conditions today announced closing of its…
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2023. First-Quarter 2023 Operating ResultsRevenue for the…
Materialise NV (NASDAQ:MTLS), a leading provider of additive manufacturing and medical software and of sophisticated 3D printing services, today announced its financial results for the first quarter ended March 31, 2023. Highlights – First Quarter 2023 Executive Chairman Peter Leys…
Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, applauds the progressive expansion of coverage for continuous glucose monitoring systems through the Non-Insured Health Benefits (NIHB) program. Following an announcement made earlier…
Deenova, leader in Europa nelle soluzioni di automazione per le farmacie ospedaliere con terapie in dose unitaria, ha annunciato oggi l’aggiudicazione di due gare competitive UniHA in Francia per tre dei suoi robot leader di mercato ACCED, all’ospedale Drôme Vivarais a Montéléger e all’ospedale…
Deenova, la compañía líder en Europa en el suministro de soluciones automatizadas para la producción de dosis unitarias en la farmacia hospitalaria anunció hoy la adjudicación de dos licitaciones competitivas UniHA (cooperativa de compradores de hospitales públicos franceses) para tres de sus…